Reinhard Laubenbacher, joint faculty member at UConn Health and The Jackson Laboratory for Genomic Medicine, has received more than $3 million from the National Institutes of Health National Institute of Allergy and Infectious Diseases to use mathematical and computational tools to explore new potential therapeutic targets to treat those affected by invasive aspergillosis.

When the otherwise harmless fungus invades the lungs of people with compromised immune systems, it can cause severe respiratory problems. Serious diseases that frequently occur as comorbidities with invasive aspergillosis in immunocompromised patients are tuberculosis and chronic obstructive pulmonary disease.